Pyrazin-2(1H)-Ones as a Novel Class of Selective A3 Adenosine Receptor Antagonists

References

• Wilson CN , MustafaSJ. Adenosine receptors in health and disease. Handbook Exp. Pharmacol.193, v–vi (2009).
   Google Scholar
• Fredholm BB , IjzermanAP, JacobsonKA, LindenJ, MüllerCE. International union of pharmacology XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev.63, 1–34 (2011).
   PubMed Web of Science ®Google Scholar
• Baraldi PG , AghadehM, TabriziMA, GessiS, BoreaPA. Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility. Chem. Rev.108, 238–263 (2008).
   PubMed Web of Science ®Google Scholar
• Jacobson KA , GaoZ. Adenosine receptors as therapeutic targets. Nat. Rev. Drug Discov.5, 247–264 (2006).
   PubMed Web of Science ®Google Scholar
• Taliani S , PugliesiI, BellandiM, La MottaC, Da SettimoF. A3 receptor ligands: present, past and future trends. Curr. Top. Med. Chem.10, 942–975 (2010).
   PubMedGoogle Scholar
• Fishman P , Bar-YehudaS. Pharmacology and therapeutic applications of A3 receptor subtypes. Curr. Top. Med. Chem.3, 463–469 (2003).
   PubMed Web of Science ®Google Scholar
• Nieber K , LewerenzA, HentschelS, VissiennonZ. Adenosine A1 and A3 receptors: neuroprotective targets with perspectives. Bioforum25, 237–240 (2002).
   Google Scholar
• Akkari R , BurbielJC, HockemeyerJ, MuellerCE. Recent progress in the development of adenosine receptor ligands as antiinflammatory drugs. Curr. Top. Med. Chem.6, 1375–1399 (2006).
   PubMed Web of Science ®Google Scholar
• Zhong Y , YangZ, HuangWC, LuoX. Adenosine, adenosine receptors and glaucoma: an updated overview. Biochim. Biophys. Acta 1830, 2882–2890 (2013).
   Google Scholar
• Brown RA , SpinaD, PageCP. Adenosine receptors and asthma. Br. J. Pharmacol.153, S446–S456 (2008).
   PubMed Web of Science ®Google Scholar
• Merighi S , MirandolaP, VaraniKet al. Pyrazolotriazolopyrimidine derivatives sensitize melanoma cells to the chemotherapeutic drugs: taxol and vindesine. Biochem. Pharmacol.66, 739–748 (2003).
   PubMed Web of Science ®Google Scholar
• Yaziji V , RodriguezD, Gutierrez-de-TeranHet al. Pyrimidine derivatives as potent and selective A3 adenosine receptor antagonists. J. Med. Chem54, 457–471 (2011).
   PubMed Web of Science ®Google Scholar
• Yaziji V , RodriguezD, CoelhoAet al. Selective and potent adenosine A3 receptor antagonists by methoxyaryl substitution on the N-(2,6-diarylpyrimidin-4-yl)acetamide scaffold. Eur. J. Med. Chem54, 457–471 (2013).
   Google Scholar
• Crespo A , El MaatouguiA, BiaginiPet al. Discovery of 3,4-dihydropyrimidin-2(1H)-ones as a novel class of potent and selective A2B adenosine receptor antagonists. ACS Med. Chem. Lett4, 1031–1036 (2013).
   PubMed Web of Science ®Google Scholar
• Azuaje J , El MaatouguiA, Pérez-RubioJM, CoelhoA, FernándezF, SoteloE. Multicomponent assembly of diverse pyrazin-2(1H)-one chemotypes. J. Org. Chem.78, 4402–4409 (2013).
   PubMed Web of Science ®Google Scholar
• Gutierrez-de-Terán H , KeränenH, AzuajeJ, RodríguezD, ÅquistJ, SoteloE. Computer-aided design of GPCR ligands. Methods Mol. Biol.1272, 1272–1291 (2015).
   Google Scholar
• Kufareva I , KatritchV, StevensRC, AbagyanR. Advances in GPCR modeling evaluated by the GPCR dock 2013 assessment: meeting new challenges. Structure22, 1120–1139 (2014).
   PubMed Web of Science ®Google Scholar
• Jaakola VP , GriffithMT, HansonMAet al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science322, 1211–1217 (2008).
   PubMed Web of Science ®Google Scholar
• Doré AS , RobertsonN, ErreyJCet al. Structure of the adenosine A2A receptor in complex with ZM241385 and the xanthines XAC and caffeine. Structure19, 1283–1293 (2011).
   PubMed Web of Science ®Google Scholar
• Baraldi PG , CacciariB, RomagnoliRet al. A3 Adenosine receptors ligands: history and perspectives. Med. Res. Rev.20, 103–128 (2000).
   PubMed Web of Science ®Google Scholar
• Higgs C , BeumingT, ShermanW. Hydration site thermodinamics explain SARs for triazolylpurines analogues binding to the A2 receptor. ACS Med. Chem. Lett.1, 160–164 (2010).
   PubMed Web of Science ®Google Scholar
• Verdonk ML , ColeJC, HartshornMJ, MurrayCW, TaylorRD. Improved protein-ligand-docking using GOLD. Proteins52, 609–623 (2003).
   PubMed Web of Science ®Google Scholar
• Schrödinger Suite, version 2012; Schrödinger, 818 LLC, 2012. www.schrodinger.com.
   Google Scholar
• Gutierrez-de-Terán H , BelloX, RodriguezD. Characterization of the dynamic events of GPCRs by automated computational simulations. Biochem. Soc. Trans.41, 205–212 (2013).
   PubMed Web of Science ®Google Scholar
• Van Der Spoel D , LindahlE, HessB, GroenhofG, MarkAE, BerendsenHJ. GROMACS: fast, flexible, and free. J. Comput. Chem.26, 1701–1718 (2005).
   PubMed Web of Science ®Google Scholar